Comment on &quot;Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials&quot;.

Leqvio (inclisiran) - Novartis

Praluent (alirocumab) - Sanofi, Regeneron

Repatha (evolocumab) - Amgen, Astellas

Lerochol (lerodalcibep-liga) - LIB Therap

Lipfendra (enlicitide) - Merck (MSD), UCB

http://www.ncbi.nlm.nih.gov/pubmed/42774982

Gaurav; Jeffrin Reneus Paul; Kotina Shridevi; Parag J Ratnakar; Vatsala Gupta

Sep 24, 2026